Uveitis
202
16
26
108
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
40 trials with published results (20%)
Research Maturity
108 completed trials (53% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
10.9%
22 terminated out of 202 trials
83.1%
-3.5% vs benchmark
21%
42 trials in Phase 3/4
37%
40 of 108 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 108 completed trials
Clinical Trials (202)
Intestinal Bacteria and Ocular Inflammatory Disease
A Study of Efficacy and Safety of GenSci048 in Subjects With Active Uveitis.
Metagenomics for Ocular Inflammation
Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis
Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing
Uveitis/Intraocular Inflammatory Disease Biobank (iBank)
A Study of Uveitis in Children <18 Years of Age
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age
Analysis of Anterior Chamber Inflammation by Optical Coherence Tomography
Imaging Quantification of Inflammation (IQI)
Genetics of Uveitis
Imaging of Uveitis Patients Receiving Injectable Fluocinolone Acetonide Implant
Evaluation of the Switch From the Original Infliximab to Its Biosimilar in Daily Practice at Cochin Hospital
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
Wide Field OCTA in Ocular Diseases
ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)
Targeting Immunosuppressive Treatment for Non-infectious Uveitis Using Aqueous Humor Cytokine Profiles
Demographics and Clinical Characteristics of Ocular Inflammatory Diseases in Singapore
Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis